Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pascale P, Delicha EM, Pricop L, Mpofu S (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 70
DOI: 10.1136/annrheumdis-2019-eular.2768
Authors with CRIS profile
Involved external institutions
Hospital of Southern Norway
Norway (NO)
Novartis AG
Switzerland (CH)
Barts Health NHS Trust
United Kingdom (GB)
Monash University
Australia (AU)
University of California, San Diego
United States (USA) (US)
Swedish Medical Center
United States (USA) (US)
Hasselt University / Universiteit Hasselt
Belgium (BE)
Norway (NO)
Novartis AG
Switzerland (CH)
Barts Health NHS Trust
United Kingdom (GB)
Monash University
Australia (AU)
University of California, San Diego
United States (USA) (US)
Swedish Medical Center
United States (USA) (US)
Hasselt University / Universiteit Hasselt
Belgium (BE)
How to cite
APA:
Mease, P.J., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J., Hall, S.,... Mpofu, S. (2018). Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial.
MLA:
Mease, Philip J., et al. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial." 2018.
BibTeX: Download